Introduction: Heat-labile toxins (LT), produced by enterotoxigenic Escherichia coli (ETEC) strains, exert potent adjuvant effects when admixed or linkedto antigens delivered via mucosal, transcutaneous or parenteral routes. There is limited information regarding the impact of preexisting immunity on the immunomodulatory properties of LT, which is frequently observed among people infected with ETEC.
Introduction
ETEC strains are considered important etiologic agents of the childhood diarrhea and represent the most common cause of the traveler's diarrhea in endemic areas. The pathogenesis induced by ETEC is associated with the production of both colonization factors, which mediate adhesion to gut cells, and entero toxins, particularly heat-stable and/or heat-labile toxin families, involved specifically with cytotoxic effects. LT toxins are characterized by an enzymatically active A subunit noncovalently linked to a pentamericring of Bpolypeptides, which is responsible for binding to cell surface receptors such asGM1 ganglioside [1, 2] . Together with cholera toxin (CT), LT shows also remarkable adjuvant activities following mucosal and parenteral administration improving both humoral and cellular immune responses against target antigens [3] [4] [5] [6] . However, the inherent toxicity of LT, even after inoculation of low amounts, has precluded its use as a vaccine adjuvant for humans, particularly under mucosal route [3, 4, 7, 8] . On the other hand, detoxified LT mutants and natural variants have demonstrated safety features after parenteral inoculation [8] [9] [10] [11] .Thus, parenteral administration of LT-derivatives represents a new and promising alternative for clinical use of this class of vaccine adjuvant.
Preexisting immunity may compromise the performance of vaccines, particularly those based on microorganisms as antigendelivery systems, such as adenovirus and Salmonella [12] [13] [14] . Such restriction may also apply to protein adjuvant, such as derivatives of LT and CT. Individuals naturally or deliberately challenged with ETEC or Vibrio cholera strains mount local and systemic antibody responses to LT [15] [16] [17] [18] . Some reports demonstrate that the rate of seroconversion directed towards LT is high, ranging from 75% to 92% at the first infection and reaching about 50-60% under rechallenge [15, 18, 19] . Additionally, it has been seen that the anti-LT antibodies in serum samples or in lymphocyte supernatants remained at increased levels following rechallenge with wild-type ETEC strain or an inactivated oralVibrio cholera vaccine [18, 20] . Collectively, these findings suggest that the natural exposure to LT or CT in endemic countries results in individuals with bloodcirculating LT-specific antibodies, which could access mucosal
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Previous studies have demonstrated that preexisting immunity to CT does not decrease induction of the antigenspecific antibody responses following mucosal immunization with attenuated forms of this toxin [21, 22] . Ugozzoli and coworkers (2001) showed that previous immunity to LT did not impact the humoral adjuvant activity following administration via mucosal routes [23] . Considering that no information regarding the impact of preexisting immunity on the adjuvanticity of LT derivatives administered via parenteral routes exists, the present study was designed to evaluate the impact of toxin-specific antibodies on the innate and adaptive immune responses, including local inflammatory effects, associated with the use of LT as a parenteral adjuvant. For that purpose, we combined a recombinant form of the dengue type 2 virus non-structural protein 1 (NS1) with type 1 LT produced by wild type ETEC strains and immunized mice via the subcutaneous route. Our results demonstrated that preexisting immunity to LT did not affect the specific antibody responses to NS1. However, local proinflammatory cytokine environment induced by LT was changed in the presence of anti-LT antibodies resulting in increased levels of IL-6 and IL-12 leading to more biased Th1 response profile.
Material and Methods
NS1 antigen and LT adjuvant. Recombinant NS1 protein was obtained as described by Amorim and coworkers (2010) [24] . E. coli BL21 strain harboring the plasmid pML19, which encoding holotoxin LT derived from reference ETEC H10407, was used for LT production [25] . Briefly, the recombinant E. coli was grown in Terrific Broth for 18 h at 37 °C with vigorous agitation (200 r.p.m. in a rotary shaker). The bacterial cell sediment was mechanically disrupted using an homogenizer (Artpeças, São Paulo, Brazil) and clarified cell extracts were applied into the immobilized D-galactose resins (Pierce, Thermo Fisher Scientific, Waltham, Massachusetts, USA) for purification of LT AB5 holotoxin, which consists of an A subunit and a pentameric B subunit, as previously described [25] . Quantification of the purified proteins was carried out by spectrophotometry (Gene Quant spectrophotomer GE Amersham Biosciences, Buckinghamshire, UK) using the formula: concentration (mg/ml) = (absorbance at 280nm/ n° tryptophan amino acid residues x 5,690 + n° tyrosine amino acid residues x 1,280) x molecular mass (Da), as previously described (Edelhoch, 1967) . The purified proteins were heated at 100 °C, submitted to 17.5% SDS-PAGE and, then, evaluated by immunoblot with an anti-LT serum, previously obtained from mouse immunizations, or a monoclonal anti-NS1 antibody kindly provided by Dr a. Roxane M. F. Piazza. The proteins were also submitted to an endotoxin removal step using ɛ-poly-L-lysine resins according to the manufacturer's instructions (Pierce®High-Capacity Endotoxin Removal Resin, Thermo Fisher Scientific, Waltham, Massachusetts, USA). After the treatment, the purified protein samples contained < 0.017 EU/μg of protein, as measured by Limulus amebocyte lysate method (Lysate LAL QCL-1000, Lonza, Basel, Switzerland).
Treatment of LT with anti-toxin antibodies or soluble GM1
The treatments encompassed the incubation of LT with anti-LT sera (0.7 µg of specific IgG/µg of toxin) or soluble GM1 ganglioside (0.5 µg of GM1/µg of toxin) (Sigma-Aldrich, St. Louis, MO, USA) in a water bath incubator at 37°C for 1 h, in a final volume of 20 µl, according to previous reported procedures [10, 26] . The NS1 antigen (10 µg) was incubated with anti-NS1 sera (7 µg of specific IgG) as described above and used as negative control for the evaluation of proinflammatory effects.
LT cytotonic assay in Y1 cell culture
The cytotonic assay was performed as previously reported [5] . The Y1 cells (5x105 cells/ml) were exposure to LT (10 µg/ml) previously treated or not with the anti-LT sera or soluble GM1. After incubation for 8 h, the cytotonic effects were assessed and images from representative fields of each treatment were captured using digital inverted microscope (EVOS FL Imaging System, Thermo Fisher Scientific). 
Mice and ethics statement

Immunizations
BALB/c mice were subcutaneously (s.c.) immunized with three doses of NS1 alone (20 µg) or NS1 co-administered with LT (1 µg) previously treated or not with anti-LT serum (0.7 µg) or soluble purified GM1 (0.5 µg) (n = 5 mice/group).Animals were bled two weeks after each dose by the submandibular vein. Serum samples were kept at -20°C.Micewere euthanized by CO2 asphyxiation two weeks after the last dose and spleen cells were harvested for cytokine analysis.
Determination of NS1 or LT-specific IgGtiters
Measurements of serum anti-NS1 or anti-LT IgG titers were carried out as previously reported [24, 27] . Briefly, microtiter plates (Nunc Maxisorp-Thermo Fisher Scientific) were coated with LT (1 µg/ml) or NS1 (1.5 µg/ml) for 16-18 h at-4°C. Two-fold serial dilutions of the tested sera were added to the plates, washed and incubated with horseradish peroxidase-conjugated goat antimouse IgG antibodies (Sigma-Aldrich, St. Louis, MO, USA) diluted to 1:3,000.The ELISA reactions were read at 492 nm in EpochTM Multi-Volume Spectrophotometer (BioTek Instruments, Vermont, USA). The results are expressed as titers, defined as the highest sample dilution with an A 492nm ≥ 0.2 above pre-immune sera.
Determination of the secreted cytokine profiles of spleen cells
The pools of spleen cells (1 x 10 7 cells/ml, in 12-well plates)
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Page 3 of 9 collected from each immunization group were cultured with NS1 (10 µg/ml) for 48 h at 37°C and5% CO 2 in RPMI medium supplemented with 10% FBS, 2mML-glutamine, 1 mM sodium pyruvate,0.5mM essential amino acids, 1mM nonessential amino acids, 10mM HEPES buffer and 50 U/ml of penicillinstreptomycin(Gibco, Thermo Fisher Scientific). Cell culture supernatants were assayed for cytokines by ELISA (BD OptEIA™ -Mouse IL5 ELISA Set and BD™ Cytometric Bead Array (CBA) Mouse Th1/Th2/Th17 cytokine kit; BD Biosciences, San Jose, CA, USA) according to the manufacturer's instructions.
Edema formation and secretion of myeloperoxidase (MPO) at subcutaneous tissues
The assays were based on protocols previously reported [8, 28] . The local edema sizes were measured at different times according to the formula: M1 x M2, where M1 and M2 represent transverse and longitudinal measurements of the swelling region, respectively. For MPO measurements, skin biopsies (100 mg) were dispersed twice for 45 sec each (T10 Basic IKA UltraTurrax Disperser -Sigma-Aldrich) in sodium phosphate buffer (0.02 M NaH 2 PO 4 , 0.015 M Na 2 EDTA, 0.1 M NaCl, pH 4.7) in a final volume of 2 ml. After centrifugation, the sediments were treated with 0.05 M sodium phosphate buffer (pH 5.4) containing 0.5% hexadecyltrimethylammonium bromide, freeze-thawed (3x), and, then, centrifuged again. The supernatants (50 µl) were incubated for 5 min at 37°C with BD OptEIA TMB substrate reagent (150 µl) in triplicate at 96-well micro titer plates (Corning Costar -Sigma Aldrich) and the absorbance was read at 450 nm (Epoch, BioTek Instruments). MPO analyses were expressed as A 450nm /mg of total protein measured by bicinchoninic acid method (BCA Protein Assay, Pierce -Thermo Fisher Scientific).
Measurement of proinflammatory cytokines
Collection of skin interstitial fluids was carried out by centrifugation according to a previously reported protocol [29] . Skin biopsies (1.5 cm 2 ) were harvested, placed with the edematous tissue facing down on a40 μMnylon cell strainer(BD Biosciences) coupled to polypropylene conical tubes (50 ml) and centrifuged (300 xg, 30 min, 4°C). The samples were re-centrifuged for 10 min to pellet the contaminating cells and the supernatants were collected for proinflammatory cytokine quantification by ELISA (BD OptEIA™ -Mouse ELISA Sets, BD Biosciences) according to the manufacturer's instructions.
Statistical analyses
The results were analyzed with Graph Pad Prism 5 software (La Jolla, CA, USA) using two-way analysis of variance (ANOVA) and Bonferroni's post-hoc test for comparisons of means. The p values <0.05 were considered statistically significant.
Results
LT purification and treatment with neutralizing agents of the cytotoxic effects
Initially, recombinant forms of the antigen (dengue virus NS1 protein) and the adjuvant (type 1 LT from reference ETEC H10407 strain) were purified by affinity chromatography at high purity levels ( Figure 1 ). The purified LT was used in the immunological assays associated or not to neutralizing agents. The amounts of antibodies or GM1 receptor required to neutralize the LT present in the vaccine formulations were determined in Y1 cells. 
Impact of toxin-specific antibodies on the inflammatory responses induced by LT
Intradermal (i.d.) administration of LT to C57BL/6 mice induces strong local inflammatory reactions (neutrophil infiltration and edema) that may persist for several days [8] . The impact of toxin-specific antibodies on the LT-associated inflammatory reactions was evaluated in mice s.c. inoculated with different amounts of LT and, subsequently, monitored for edema formation and local production of MPO. As shown in Figure 3A and B, edema formation peaked 48 h after inoculation of 10 µg of LT and BALB/c mice controlled the inflammatory response more efficiently than C57BL/6 mice. Edema formation and MPO production were measured, both in BALB/c and C57BL/6 mice, after administration of 10 μg of LT previously incubated with 7 μg of anti-LT antibodies (LT-Ab) or with 5 μg of soluble GM1 (LT-GM1) ( Figure 3C to F) . Inoculation of NS1 immune complexes (NS1 protein plus anti-NS1 serum) did not induce edema and neutrophil recruitment into s.c. tissue (data not shown). In addition, mice inoculated with LT treated with GM1 showed significantly smaller edema and lower local MPO production than animals inoculated with LT ( Figure 3C to F) . In contrast, mice inoculated with LT previously incubated with anti-LT antibodies developed edema sizes and local neutrophil infiltration similar to mice inoculated only with LT ( Figure 3C to F) . We also measured the local cytokine production in mice s.c. inoculated with LT admixed with anti-LT antibodies or purified GM1. The presence of IL-10, TNF-α and IFN-γ was not detected in tissue samples of all tested groups. In contrast, inoculation of LT admixed with anti-LT antibodies enhanced the production of IL-6 and IL-12, but did not interfere with the IL-1β levels induced by LT ( Figure   4 ). Additionally, pre-exposure of LT to purified GM1 strongly suppressed the local production of IL-6, IL-12 and IL-1βsecretion (Figure 4 ). These findings demonstrate that treatment with GM1 abrogates the local LT inflammatory effects; whereas anti-LT antibodies did not ablate the LT local inflammatory reactions but modulate the pro-inflammatory cytokines secreted by local cells.
Exposure to antibodies modulates the adaptive immunitycytokine responses induced by LT
The impact of the preexisting immunity was evaluated with LT-adjuvanted vaccine formulations in which LT was incubated with anti-LT antibodies before inoculation into BALB/c mice. Mice were immunized with vaccine formulations containing NS1 and LT previously admixed with anti-LT antibodies or GM1. As shown in Figure5A, previous incubation of LT with anti-LT antibodies did not reduce the immunogenicity of the toxin, as measured by the amount of anti-LT antibodies in vaccinated mice. In contrast, mice immunized with LT previously admixed with GM1 showed significantly lower anti-LT responses (Figure5A). These results indicated that previous exposure to LT-specific antibodies did not impact the immunogenicity of LT, while administration of LT associated to GM1 marked reduced the immunogenicity of the toxin.
Regarding LT adjuvanticity, in vitro incubation of LT and anti-LT antibodies or GM1 did not impact the adjuvant effects of LT, as measured by the induced serum anti-NS1 IgG responses ( Figure 5B) . Similarly, the antigen-specific IgG subclass responses detected in mice immunized with LT and NS1 were not altered after co-administration of the vaccine formulation containing anti-LT antibodies or GM1 (FigureS1) . Concerning the T cell adjuvant
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Discussion
Modern subunit vaccines require potent and versatile adjuvants for inducing efficient and long live protective immunity. Heat-labile toxins derived from ETEChavestrong adjuvant effects, demonstrated both at preclinical and clinical conditions, but suffer with safety concerns according to the administration route. In addition, LT derivatives show inherent immunogenicity that may preclude the efficacy of LT-adjuvanted vaccines at endemic regions or at conditions of multiple immunizations. Although this issue has been previously investigated following mucosal delivery, the impact of preexisting immunity on the adjuvant properties of LT in vaccine formulations delivered via parenteral routes remains to be elucidated. In this study, we investigated whether preexisting immunity impairs the humoral and cellular adjuvant properties of LT following s.c. vaccination and our findings demonstrated that previous immunity did not impact the humoral adjuvant activity of LT. We observed also that preexisting immunity did not reduce the local inflammatory signs induced by native LT but our results demonstrated that the presence of LTAb immune complexes shift the cytokine expression patterns of both innate and adaptive immune cells. Collectively, the present study opens perspectives for the use of LT, and its derivatives, as parenteral adjuvants and brings relevant information regarding immune response modulation by this class of adjuvants.
In prior studies, preexisting immunity against CT or LT did not impair the antigen-specific antibodies responses induced by this class of adjuvants following mucosal administration [21] [22] [23] . Nonetheless, i.n. delivered LT administration, including non-toxic derivatives, has raised safety issues for humans [3, 30, 31] , while similar concerns have not been observed following non-toxic LT administration by parenteral routes. Preclinical studies based on LT derivatives delivered via parenteral routes have demonstrated that these molecules are safe and robust inducers of humoral and cellular immune responses [8] [9] [10] [11] . In this context the present study is the first to demonstrate that preexisting immunity to LT did not affect immunogenicity and humoral adjuvant effects of LT, thus adding another supporting evidence for the potential usefulness of LT as parenteral delivered adjuvants.
Here we have also seen that exposure of LT to anti-toxin antibodies change the cytokine secretion pattern of immune cells biasing antigen-specific T cell responses to the Th1 type. In concordance with this result, we detected increasedIL-6 and IL-12 level sat the inoculation site in mice treated with LT-Ab complexes. In fact, IL-12 is strongly associated to Th1 polarization and to immunosuppression of Th2-type response [32] [33] [34] . On the other hand, IL-6 generally leads to B cell activation and a Th2 phenotype [35] [36] [37] . However, previous reports have demonstrated that the IL-6 pleiotropic effects may either lead naive The cells to differentiate into Th1 or yetnotinterfere in the lpercell profile when IL-12 is up regulated [38] [39] [40] . Based on our findings, previous immunity against LT may change proinflammatory cytokines produced at the inoculation site, and, thereby, fine-tune the pattern of the adaptive immune responses mediated by T lymphocytes.
Previous study has demonstrated that neutrophils represent the predominant immune cells infiltrated into edema observed after i.d. inoculation of native LT [8] . Here, we demonstrated that LT is capable of generating edema and neutrophil recruitment to the inoculation site, concomitantly with local IL-1β increases and systemic activation of Th17-type response. In addition, our results demonstrated that the presence of preexisting immunity to LT did not reduce these parameters of inflammatory reactions. Our findings also show that the LT-soluble GM1 complexes drastically reduce swelling diameter and neutrophil migration, as well as strongly decrease the IL-1β and IL-17 levels. Consistently with our findings, IL-1β has been implicated with neutrophil recruitment or, together with IL1-α and IL-23, on modulation of CD4+ T cell to the Th17 profile [41] [42] [43] . Moreover, data in the literature demonstrated that LT enhances antigen-specific Th17 cells in anIL-1β and inflamma some activation dependent manner [42] . Thus, the present evidences support the involvement of IL-1β on the modulation of Th17 cells and local neutrophil recruitment, but further studies are required to elucidate the additional role of other proinflammatorycytokines and chemokines.
In conclusion, the evidences presented here demonstrate that preexisting immunity does not negatively impact the humoral adjuvant effects of LT following s.c.vaccination, but may alter the cytokine signatures of innate immune cells and the antigen-specific adaptive immunity biasing it to a Th1 pattern. Our findings, together with those published previously by our research group and others, demonstrate that parenteral administration routes represent robust, safe and efficacious alternatives to delivery of LT-based adjuvants for the mounting of effect or humoral and cellular immunity despite preexisting immunity to the toxin.
